Trials
1 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.”In the company’s words, NCT05879432 on ClinicalTrials.gov
- Tested for
- Acute Kidney Injury, Cardiac Surgery
- Main trialPhase 2
- “To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria: 1. Increase in baseline (pre-surgery) serum creatinine (SCr) by ≥26.5 μmol/L (≥0.3 mg/dL) within 7 days; OR 2. Increase in baseline SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the first 7 days following surgery; OR 3. Urine output \< 0.5 mL/kg/h for \>6 hours.”In the company’s words, NCT05879432 on ClinicalTrials.gov
- Other names
- Metablok
Other drugs for Acute Kidney Injury
- QRX-3Ebima Clifford Okundaye · Phase 2/3
- PrismocitrateVantive Health LLC · Phase 3
- AZD4144AstraZeneca · Phase 2
- R2R01River 2 Renal Corp. · Phase 2
- CSL889CSL Behring · Phase 2
- Allogeneic HB-adMSCsHope Biosciences LLC · Phase 1/2
Coming up1
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Mar 2027 | LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery | |
| Phase 2Completed | 27 May 2021 | LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026